Welcome to our dedicated page for Spyre Therapeutics news (Ticker: $SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spyre Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spyre Therapeutics's position in the market.
Rhea-AI Summary
Spyre Therapeutics, Inc. announced the approval of grants of stock options to 4 non-executive employees as equity inducement awards. These options were granted under the 2018 Equity Inducement Plan with a 10-year term and an exercise price of $33.87 per share. The options will vest over time, subject to continuous service with Spyre.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
-
Rhea-AI Summary
Spyre Therapeutics, Inc. announced the approval of stock options for 3 non-executive employees under the 2018 Equity Inducement Plan. The options total 90,100 shares with a 10-year term and an exercise price of $37.00 per share. Vesting occurs over time based on the employees' start date and continuous service with Spyre.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.27%
Tags
-
Rhea-AI Summary
Spyre Therapeutics, Inc. announces a private investment in public equity financing, expecting to raise $180 million through the sale of Series B non-voting convertible preferred stock to various investors, including Adage Capital Partners LP and Perceptive Advisors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.68%
Tags
Rhea-AI Summary
Spyre Therapeutics, Inc. announces the approval of stock options for non-executive employees under the 2018 Equity Inducement Plan. The options were granted with a 10-year term and an exercise price of $29.90 per share, vesting over time based on the employee's tenure with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.96%
Tags
-
Rhea-AI Summary
Spyre Therapeutics, Inc. announced a corporate name change, appointment of a new CEO, and began trading on Nasdaq under the symbol 'SYRE'. The company raised $180 million in private placement equity financing and has a strong financial position with $340 million in cash. They have promising drug candidates in their pipeline for inflammatory bowel disease, with SPY001 and SPY002 on track for first-in-human studies in 2024. The company aims to demonstrate potential best-in-class properties of their investigational medicines in the coming years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
-
Rhea-AI Summary
Spyre Therapeutics, Inc. (NASDAQ: SYRE) will participate in the TD Cowen 44th Annual Health Care Conference. CEO Cameron Turtle will join the Inflammation & Immunology Corporate Panel Discussion on March 5, 2024. Investors can access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
Rhea-AI Summary
Spyre Therapeutics, Inc. (SYRE) and its research partner, Paragon Therapeutics, Inc., have announced that their co-lead product candidates, SPY001 and SPY002, have been accepted for presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation. These candidates are fully optimized and half-life extended antibodies targeting α4β7 and TL1A, respectively, for the treatment of Inflammatory Bowel Disease (IBD). The preclinical findings supporting these programs will be presented at the ECCO Congress, with potential for significant improvement compared to today's approved therapies. Phase 1 clinical studies are expected to be initiated this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
-
Rhea-AI Summary
Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced the appointment of Mark C. McKenna to its Board of Directors. McKenna brings a strong track record of corporate leadership and product development, particularly in Inflammatory Bowel Disease (IBD). The company aims to advance its potentially best-in-class antibodies targeting α4β7 and TL1A into clinical trials this year, with McKenna's guidance. McKenna's impressive career includes being the former President, CEO, and Chairman of the Board of Directors of Prometheus Biosciences, Inc., which was acquired by Merck & Co., Inc. for approximately $10.8 billion. Spyre had a successful 2023, raising $390M through the capital markets with top-tier biotechnology investors, positioning the company to advance their pipeline candidates into the clinic. In connection with McKenna's appointment, Alison Lawton has resigned from the Company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
-
Rhea-AI Summary
Spyre Therapeutics, Inc. announced the approval of stock options for two non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan. The options were granted with a 10-year term and an exercise price equal to $25.86. They shall vest and become exercisable over time, subject to continuous service with Spyre. The options were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Spyre Therapeutics, Inc. (SYRE) announced the approval of stock options for non-executive employees as equity inducement awards under the 2018 Equity Inducement Plan. The options were granted with a 10-year term and an exercise price of $15.81, vesting over time based on the employees' start date and continuous service with Spyre.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Spyre Therapeutics, Inc.
Nasdaq:SYRE
SYRE Rankings
SYRE Stock Data
1.38B
22.93M
5.42%
84.56%
8.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
WALTHAM
About SYRE
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f